Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket

Proceedings of the National Academy of Sciences of the United States of America

Volumn 114, Issue 8, 2017, Pages 2066-2071

  Sun, Bingfa ^a   Bachhawat, Priti ^a   Chu, Matthew Ling Hon ^a   Wood, Martyn ^b   Ceska, Tom ^b   Sands, Zara A ^b   Mercier, Joel ^b   Lebon, Florence ^b   Kobilka, Tong Sun ^a   Kobilka, Brian K ^a,c  

^a ConfometRx Inc ^*  (United States)

^b UCB PHARMA   (Belgium)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

A2A adenosine receptor; Allosteric; GPCR; Parkinson's disease; Structure

Indexed keywords

4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE A2A RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; TYROSINE DERIVATIVE; ADENOSINE A2 RECEPTOR ANTAGONIST; ANTIPARKINSON AGENT; LIGAND; NR2B NMDA RECEPTOR; TRIAZINE DERIVATIVE; TRIAZOLE DERIVATIVE; TYROSINE;

ALLOSTERISM; ARTICLE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIFFUSION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; MICELLE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STRUCTURE; ALLOSTERIC SITE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; HUMAN; METABOLISM; PARKINSON DISEASE; PROTEIN TERTIARY STRUCTURE; SF9 CELL LINE; SPODOPTERA; X RAY CRYSTALLOGRAPHY;

ADENOSINE A2 RECEPTOR ANTAGONISTS; ALLOSTERIC SITE; ANIMALS; ANTIPARKINSON AGENTS; CRYSTALLOGRAPHY, X-RAY; HUMANS; LIGANDS; PARKINSON DISEASE; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ADENOSINE A2A; RECEPTORS, N-METHYL-D-ASPARTATE; SF9 CELLS; SPODOPTERA; TRIAZINES; TRIAZOLES; TYROSINE;

EID: 85013250295     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1621423114     Document Type: Article

References (30)

1. de Lera Ruiz M, Lim YH, Zheng J (2014) Adenosine A2A receptor as a drug discovery target. J Med Chem 57(9):3623-3650.
2. Shook BC, Jackson PF (2011) Adenosine A(2A) receptor antagonists and Parkinson's disease. ACS Chem Neurosci 2(10):555-567.
3. Pinna A, Wardas J, Simola N, Morelli M (2005) New therapies for the treatment of Parkinson's disease: Adenosine A2A receptor antagonists. Life Sci 77(26):3259-3267.
4. Milne GR, Palmer TM (2011) Anti-inflammatory and immunosuppressive effects of the A2A adenosine receptor. Sci World J 11:320-339.
5. Bara-Jimenez W, et al. (2003) Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. Neurology 61(3):293-296.
6. Michel A, Downey P, Nicolas JM, Scheller D (2014) Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease. PLoS One 9(12):e114086.
7. Lebon G, Edwards PC, Leslie AG, Tate CG (2015) Molecular determinants of CGS21680 binding to the human adenosine A2A receptor. Mol Pharmacol 87(6):907-915.
8. Liu W, et al. (2012) Structural basis for allosteric regulation of GPCRs by sodium ions. Science 337(6091):232-236.
9. Congreve M, et al. (2012) Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design. J Med Chem 55(5):1898-1903.
10. Hino T, et al. (2012) G-protein-coupled receptor inactivation by an allosteric inverse-agonist antibody. Nature 482(7384):237-240.
11. Xu F, et al. (2011) Structure of an agonist-bound human A2A adenosine receptor. Science 332(6027):322-327.
12. Doré AS, et al. (2011) Structure of the adenosine A(2A) receptor in complex with ZM241385 and the xanthines XAC and caffeine. Structure 19(9):1283-1293.
13. Lebon G, et al. (2011) Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation. Nature 474(7352):521-525.
14. Jaakola VP, et al. (2008) The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 322(5905):1211-1217.
15. Caffrey M (2015) A comprehensive review of the lipid cubic phase or in meso method for crystallizing membrane and soluble proteins and complexes. Acta Crystallogr F Struct Biol Commun 71(Pt 1):3-18.
16. Caffrey M, Cherezov V (2009) Crystallizing membrane proteins using lipidic mesophases. Nat Protoc 4(5):706-731.
17. Thorsen TS, Matt R, Weis WI, Kobilka BK (2014) Modified T4 lysozyme fusion proteins facilitate G protein-coupled receptor crystallogenesis. Structure 22(11):1657-1664.
18. Chun E, et al. (2012) Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure 20(6):967-976.
19. Russo Krauss I, Merlino A, Vergara A, Sica F (2013) An overview of biological macromolecule crystallization. Int J Mol Sci 14(6):11643-11691.
20. Ballesteros JA, Weinstein H (1995) Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci 25:366-428.
21. Palczewski K, et al. (2000) Crystal structure of rhodopsin: A G protein-coupled receptor. Science 289(5480):739-745.
22. Chien EY, et al. (2010) Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science 330(6007):1091-1095.
23. De Zwart M, et al. (1999) Potent antagonists for the human adenosine A2B receptor. Derivatives of the triazolotriazine adenosine receptor antagonist ZM241385 with high affinity. Drug Dev Res 48:95-103.
24. Otwinowski Z, Minor W (1997) Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 276:307-326.
25. McCoy AJ, et al. (2007) Phaser crystallographic software. J Appl Cryst 40(Pt4):658-674.
26. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66(Pt 4):486-501.
27. Murshudov GN, Vagin AA, Dodson EJ (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr 53(Pt 3):240-255.
28. Chen VB, et al. (2010) MolProbity: All-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr 66(Pt 1):12-21.
29. Bochevarov AD, et al. (2013) Jaguar: A high-performance quantum chemistry software program with strengths in life and materials sciences. Int J Quantum Chem 113(18):2110-2142.
30. Palmer TM, Poucher SM, Jacobson KA, Stiles GL (1995) 125I-4-(2-[7-amino-2-[2-furyl] [1,2,4]triazolo[2,3-a][1,3,5] triazin-5-yl-amino]ethyl)phenol, a high affinity antagonist radioligand selective for the A2a adenosine receptor. Mol Pharmacol 48(6):970-974.